HK1185018A1 - Compounds and methods for inhibiting phosphate transport - Google Patents

Compounds and methods for inhibiting phosphate transport

Info

Publication number
HK1185018A1
HK1185018A1 HK13112548.7A HK13112548A HK1185018A1 HK 1185018 A1 HK1185018 A1 HK 1185018A1 HK 13112548 A HK13112548 A HK 13112548A HK 1185018 A1 HK1185018 A1 HK 1185018A1
Authority
HK
Hong Kong
Prior art keywords
compounds
methods
phosphate transport
inhibiting phosphate
inhibiting
Prior art date
Application number
HK13112548.7A
Other languages
English (en)
Chinese (zh)
Inventor
Jason G Lewis
Jeffrey W Jacobs
Nicholas Reich
Michael R Leadbetter
Noah Bell
Han-Ting Chang
Tao Chen
Marc Navre
Dominique Charmot
Christopher Carreras
Eric Labonte
Original Assignee
Ardelyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardelyx Inc filed Critical Ardelyx Inc
Publication of HK1185018A1 publication Critical patent/HK1185018A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
HK13112548.7A 2010-07-07 2013-11-07 Compounds and methods for inhibiting phosphate transport HK1185018A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36212110P 2010-07-07 2010-07-07
PCT/US2011/043261 WO2012006473A1 (en) 2010-07-07 2011-07-07 Compounds and methods for inhibiting phosphate transport

Publications (1)

Publication Number Publication Date
HK1185018A1 true HK1185018A1 (en) 2014-02-07

Family

ID=45441562

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13112548.7A HK1185018A1 (en) 2010-07-07 2013-11-07 Compounds and methods for inhibiting phosphate transport

Country Status (6)

Country Link
US (2) US8815910B2 (xx)
EP (1) EP2590655B1 (xx)
JP (1) JP5827326B2 (xx)
ES (1) ES2547890T3 (xx)
HK (1) HK1185018A1 (xx)
WO (1) WO2012006473A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276242B2 (en) 2009-07-21 2014-05-29 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590655B1 (en) 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
MX342521B (es) 2011-10-27 2016-10-03 Astellas Pharma Inc Derivado de n-tienilbenzamida sustituido con aminoalquilo.
WO2013129435A1 (ja) * 2012-02-28 2013-09-06 協和発酵キリン株式会社 縮環チオフェン誘導体
WO2014003153A1 (ja) * 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
RS58969B1 (sr) 2013-04-12 2019-08-30 Ardelyx Inc Jedinjenja koja se vezuju za nhe3 i postupci za inhibiranje transporta fosfata
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
WO2015066593A1 (en) * 2013-11-04 2015-05-07 Keryx Biopharmaceuticals, Inc. Ferric citrate for reducing cardiac failure in chronic kidney disease patients
CN103755695B (zh) * 2013-12-20 2016-04-06 陕西理工学院 一种具有抗肿瘤活性的酰胺类化合物及其应用
WO2015108038A1 (ja) * 2014-01-17 2015-07-23 第一三共株式会社 エチレングリコール化合物
BR112016020067B1 (pt) 2014-03-06 2021-08-31 Bayer Cropscience Aktiengesellschaft Compostos heterocíclicos como pesticidas.
DE102014019388A1 (de) * 2014-12-29 2016-06-30 Susanne Wagner Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
EP3429693B1 (en) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3565811A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
BR112020005390A2 (pt) 2017-09-20 2020-09-29 Mersana Therapeutics, Inc. composições e métodos para prever a resposta à terapia direcionada ao napi2b
CN113194999A (zh) 2018-08-17 2021-07-30 梅尔莎纳医疗公司 NaPi2b靶向的聚合物抗体-药物缀合物及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
EP1175425A2 (en) 1999-01-21 2002-01-30 The Board Of Regents, The University Of Texas System Inhibitors of intestinal apical membrane na/phosphate co-transportation
CO5190714A1 (es) * 1999-07-20 2002-08-29 Smithkline Beecham Corp Inhibidores del transporte de fosfato
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US20030212074A1 (en) * 2000-05-02 2003-11-13 Dimitri Gaitanopoulos Phosphate transport inhibitors
US20030216449A1 (en) 2001-05-11 2003-11-20 Joseph Weinstock Phosphate transport inhibitors
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2004085382A1 (ja) 2003-03-27 2004-10-07 Kirin Beer Kabushiki Kaisha 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
KR20070034075A (ko) 2004-06-25 2007-03-27 스트론틴 에이피에스 스트론튬과 비타민 ｄ를 함유하는 조성물 및 그의 용도
US7700628B2 (en) 2004-11-24 2010-04-20 Eli Lilly And Company Aromatic ether derivatives useful as thrombin inhibitors
EP2590655B1 (en) 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CA2880432C (en) 2012-08-21 2023-03-14 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Also Published As

Publication number Publication date
JP2013533886A (ja) 2013-08-29
US20150164904A1 (en) 2015-06-18
US9289430B2 (en) 2016-03-22
WO2012006473A1 (en) 2012-01-12
US20130336921A1 (en) 2013-12-19
JP5827326B2 (ja) 2015-12-02
EP2590655A1 (en) 2013-05-15
US8815910B2 (en) 2014-08-26
EP2590655B1 (en) 2015-06-24
EP2590655A4 (en) 2013-12-18
ES2547890T3 (es) 2015-10-09

Similar Documents

Publication Publication Date Title
EP2591354A4 (en) COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
EP2590656A4 (en) COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
HK1185018A1 (en) Compounds and methods for inhibiting phosphate transport
HK1184972A1 (zh) 化合物及用於抑制磷酸鹽轉運的方法
HK1185072A1 (zh) 化合物及用於抑制磷酸鹽轉運的方法
IL280864A (en) Compounds and methods for inhibiting phosphate transport
IL284624A (en) NHE3-binding compounds and methods for inhibiting phosphate transport
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
HK1187323A1 (en) Transportation system
SI2523864T1 (sl) Naprava za transport predmetov
HK1162204A1 (en) Method and system for locating objects
EP2549863A4 (en) COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORTATION
PL2558378T3 (pl) Pojemnik transportowy
IL220812A0 (en) Compounds and methods
GB2489082B (en) Transport system for heavy-duty equipment
EP2523560A4 (en) CONNECTIONS AND METHODS
EP2569921A4 (en) SYSTEM AND METHOD FOR PROVIDING A RELIABLE MEMORY
EP2568831A4 (en) DISINFECTION SYSTEM AND METHOD
EP2566876A4 (en) METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES
EP2635439A4 (en) SYSTEM AND METHOD FOR TRANSPORTING SUBSTRATES
GB2485759B (en) Transport
EP2646205A4 (en) METHOD AND SYSTEM FOR HANDLING OBJECTS
GB201015413D0 (en) Transportation system
GB201018597D0 (en) Inhibitors